Condition
Neuroendocrine Carcinoma
ClinicalTrials.gov condition label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 31 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
31 shownAutologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory DiseaseNCT07509034 · 2026-10-12
RECRUITINGTarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)NCT06937905 · 2026-02-06
RECRUITINGZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaNCT07038096 · 2025-09-23
RECRUITINGDose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.NCT06440057 · 2024-08-29
RECRUITINGClinical Application of the J-PET Scanner PrototypeNCT06242119 · 2024-03-07
RECRUITINGStudy of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaNCT05978284 · 2023-10-27
RECRUITINGNeuroendocrine Transformation in RB1/TP53 Inactivated NSCLCNCT06369181 · 2021-01-01
RECRUITINGThe Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]NCT02688894 · 2016-06-10
RECRUITINGA Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and ProstateNCT06941480 · 2026-09-01
NOT_YET_RECRUITINGSafety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor MalignanciesNCT06577987 · 2024-08-14
ACTIVE_NOT_RECRUITINGA Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine CarcinomasNCT05619744 · 2023-01-23
COMPLETEDIadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NETNCT05420636 · 2022-12-21
TERMINATEDNP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasNCT05262556 · 2022-12-15
COMPLETEDSimultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer PatientsNCT05396118 · 2022-05-18
UNKNOWNNeuroendocrine Tumors - Patient Reported OutcomesNCT05064150 · 2022-05-10
ACTIVE_NOT_RECRUITINGPrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANECNCT06400654 · 2021-07-05
UNKNOWNNiraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine CarcinomasNCT04701307 · 2021-02-01
ACTIVE_NOT_RECRUITINGA Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)NCT04471727 · 2020-12-14
ACTIVE_NOT_RECRUITINGPembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine CarcinomaNCT03901378 · 2019-10-02
WITHDRAWNPh I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid TumorsNCT03647163 · 2019-04-09
ACTIVE_NOT_RECRUITINGNivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)NCT03591731 · 2019-01-02
COMPLETEDNivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine CancerNCT03728361 · 2018-12-31
COMPLETEDStudy of CVM-1118 for Patients With Advanced Neuroendocrine TumorsNCT03600233 · 2018-12-15
ACTIVE_NOT_RECRUITINGSecond-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine CarcinomaNCT03837977 · 2018-11-13
COMPLETEDA Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsNCT03517488 · 2018-07-10
COMPLETEDStereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung CancerNCT03110978 · 2017-06-26
ACTIVE_NOT_RECRUITINGAtezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsNCT03074513 · 2017-03-03
ACTIVE_NOT_RECRUITINGPEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung CancersNCT02936323 · 2016-12-08
COMPLETEDPhase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in HumansNCT02970786 · 2016-11-01
UNKNOWNStudy of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic OriginNCT02687958 · 2015-05-01
UNKNOWNCisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung CancerNCT01642251 · 2012-09-28
COMPLETEDCommon interventions
NivolumabBIOLOGICAL2ZG006BIOLOGICAL2177Lu-DTPA-SC16.56BIOLOGICAL118F-FDGDRUG1AtezolizumabBIOLOGICAL1AtezolizumabDRUG1Autologous B7-H3 CAR TDRUG1BevacizumabBIOLOGICAL1CID-078 MonotherapyDRUG1CisplatinDRUG1CVM-1118DRUG1CyclophosphamideDRUG1DocetaxelDRUG1DostarlimabBIOLOGICAL1EtoposideDRUG1EverolimusDRUG1FludarabineDRUG1FluorouracilDRUG1Folinic AcidDRUG1GocatamigBIOLOGICAL1IadademstatDRUG1Ifinatamab Deruxtecan (I-DXd)BIOLOGICAL1Injection of 68Ga-NODAGA-E(c[RGDyK])2DRUG1Injection of hyperpolarized [1-13C]PyruvateDRUG1IpilimumabDRUG1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
M.D. Anderson Cancer Center
3
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
3
Copenhagen University Hospital, Rigshospitalet
2
Intergroupe Francophone de Cancerologie Thoracique
2
National Cancer Institute (NCI)
2
Amr Mohamed MD
1
Circle Pharma
1
Dwight Owen
1
European Institute of Oncology
1
Fox Chase Cancer Center
1
Fudan University
1
Gruppo Oncologico Italiano di Ricerca Clinica
1
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1
Hoffmann-La Roche
1
Jagiellonian University
1
Trial status mix
ACTIVE_NOT_RECRUITING8
COMPLETED8
RECRUITING8
UNKNOWN4
NOT_YET_RECRUITING1
TERMINATED1
WITHDRAWN1
Phase mix
PHASE218
PHASE114
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.